EA201400392A1 - ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb - Google Patents
ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-ErbInfo
- Publication number
- EA201400392A1 EA201400392A1 EA201400392A EA201400392A EA201400392A1 EA 201400392 A1 EA201400392 A1 EA 201400392A1 EA 201400392 A EA201400392 A EA 201400392A EA 201400392 A EA201400392 A EA 201400392A EA 201400392 A1 EA201400392 A1 EA 201400392A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- rev
- erb
- substituted
- agonists
- triazolopiridazines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
Изобретение относится к новым 6-замещенным 1,2,4-триазоло[4,3-b]пиридазинам, которые являются агонистами Rev-Erb. Такие соединения и фармацевтические композиции, включающие их, являются подходящими средствами для лечения любого заболевания, при котором активация Rev-Erb оказывает терапевтическое действие, например, при воспалительных и связанных с циркадным ритмом расстройствах или кардиометаболических заболеваниях.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11306234 | 2011-09-27 | ||
EP12163795 | 2012-04-11 | ||
PCT/EP2012/069014 WO2013045519A1 (en) | 2011-09-27 | 2012-09-27 | Derivatives of 6-substituted triazolopyridazines as rev-erb agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201400392A1 true EA201400392A1 (ru) | 2014-09-30 |
EA029834B1 EA029834B1 (ru) | 2018-05-31 |
Family
ID=46934586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201400392A EA029834B1 (ru) | 2011-09-27 | 2012-09-27 | ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb |
Country Status (13)
Country | Link |
---|---|
US (2) | US9586963B2 (ru) |
EP (1) | EP2760866B1 (ru) |
JP (1) | JP6042438B2 (ru) |
CN (1) | CN104024259B (ru) |
AU (1) | AU2012314501B2 (ru) |
BR (1) | BR112014006924B1 (ru) |
CA (1) | CA2848518C (ru) |
EA (1) | EA029834B1 (ru) |
HK (1) | HK1200448A1 (ru) |
IL (1) | IL231501B (ru) |
MX (1) | MX356683B (ru) |
WO (1) | WO2013045519A1 (ru) |
ZA (1) | ZA201402975B (ru) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150023722A (ko) * | 2012-06-12 | 2015-03-05 | 애브비 인코포레이티드 | 피리디논 및 피리다지논 유도체 |
EP2931272A1 (en) | 2012-12-12 | 2015-10-21 | The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System | Methods of treating hepatic fibrosis and associated diseases by regulating rev-erb activity |
US9872851B2 (en) * | 2012-12-12 | 2018-01-23 | The Charlotte-Mecklenburg Hospital Authority | Methods of treating portal hypertension |
ITTO20130816A1 (it) | 2013-10-09 | 2015-04-10 | Fond Istituto Italiano Di Tecnologia | Antagonisti di rev-erb diarilalchilaminici e loro uso come farmaci |
CN105596336B (zh) * | 2016-01-18 | 2018-05-22 | 暨南大学 | 化合物sr8278在制备治疗i型糖尿病角膜病变药物中的应用 |
US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
PT3548033T (pt) | 2016-11-28 | 2024-08-09 | Praxis Prec Medicines Inc | Compostos e respectivos métodos de utilização |
US11389427B2 (en) | 2017-02-10 | 2022-07-19 | Case Western Reserve University | Compositions and methods of treating cardiac hypertrophy and heart failure |
WO2018148745A1 (en) | 2017-02-13 | 2018-08-16 | Praxis Precision Medicines , Inc. | Compounds and their methods of use |
WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
MX2020005818A (es) * | 2017-12-19 | 2020-08-20 | Bristol Myers Squibb Co | Triazol azoles de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa). |
BR112020024379A2 (pt) | 2018-05-30 | 2021-03-02 | Praxis Precision Medicines, Inc. | moduladores de canais iônicos |
US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
CN112409340B (zh) | 2019-08-21 | 2022-03-18 | 海创药业股份有限公司 | 卤素取代的苯醚类化合物及其用途 |
US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
AR121846A1 (es) * | 2020-04-16 | 2022-07-13 | Teijin Pharma Ltd | Derivado de arilo o heteroarilo |
CN114907333B (zh) * | 2022-05-11 | 2023-07-04 | 中国人民解放军军事科学院军事医学研究院 | 环丙甲酰胺衍生物及其制备方法和用途 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5233583B2 (ru) * | 1972-06-15 | 1977-08-29 | ||
JPS603080B2 (ja) * | 1976-08-10 | 1985-01-25 | 三菱化学株式会社 | S―トリアゾロ〔3,4 ―α〕〔5,6,7,8〕テトラヒドロ フタラジン類 |
JPS54128595A (en) | 1978-03-29 | 1979-10-05 | Nippon Nohyaku Co Ltd | Triazolopyridazine compound |
DE3222342A1 (de) | 1982-06-14 | 1983-12-15 | Hoechst Ag, 6230 Frankfurt | 6-aryl-1,2,4-triazolo (4,3-b) pyridazin-3-carbaminate, ihre herstellung und sie enthaltende arzneimittel |
GB9813576D0 (en) | 1998-06-24 | 1998-08-19 | Merck Sharp & Dohme | Therapeutic agents |
FR2780512B1 (fr) | 1998-06-25 | 2003-10-17 | Lipha | Utilisation de recepteurs de la famille rev-erb pour le criblage de substances utiles dans le traitement des dysfonctionnements du metabolisme lipidique |
FR2834996B1 (fr) | 2002-01-18 | 2004-12-03 | Genfit S A | Methode d'identification de substances capables de moduler la differenciation adipocytaire |
JPWO2004053124A1 (ja) | 2002-12-06 | 2006-04-13 | 塩野義製薬株式会社 | 糖尿病治療剤又は予防剤のスクリーニング方法 |
JP4817661B2 (ja) * | 2002-12-18 | 2011-11-16 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとしてのトリアゾロピリダジン |
WO2005076004A1 (en) | 2004-02-10 | 2005-08-18 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human nuclear receptor nr1d1 (nr1d1) |
PL2081937T3 (pl) | 2006-10-23 | 2013-01-31 | Sgx Pharmaceuticals Inc | Triazolopirydazynowe modulatory kinaz białkowych |
US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
WO2009086303A2 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
US8642583B2 (en) * | 2008-10-30 | 2014-02-04 | Janssen Pharmaceutica Nv | Serotonin receptor modulators |
FR2941950B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
JP5321197B2 (ja) * | 2009-03-31 | 2013-10-23 | Dic株式会社 | 含フッ素ラジカル重合性ブロック共重合体、それを用いた活性エネルギー線硬化型樹脂組成物及び含フッ素ラジカル重合性ブロック共重合体の製造方法 |
PT2464645T (pt) | 2009-07-27 | 2017-10-11 | Gilead Sciences Inc | Compostos heterocíclicos fusionados como moduladores do canal de iões |
WO2011022619A1 (en) * | 2009-08-20 | 2011-02-24 | Glaxo Group Limited | TREATING INFLAMMATORY DISEASES BY ADMINISTRATION OF REV-ERB α LIGANDS |
-
2012
- 2012-09-27 AU AU2012314501A patent/AU2012314501B2/en not_active Ceased
- 2012-09-27 CN CN201280055722.6A patent/CN104024259B/zh not_active Expired - Fee Related
- 2012-09-27 WO PCT/EP2012/069014 patent/WO2013045519A1/en active Application Filing
- 2012-09-27 EP EP12766084.3A patent/EP2760866B1/en not_active Not-in-force
- 2012-09-27 MX MX2014003637A patent/MX356683B/es active IP Right Grant
- 2012-09-27 JP JP2014532375A patent/JP6042438B2/ja not_active Expired - Fee Related
- 2012-09-27 BR BR112014006924-7A patent/BR112014006924B1/pt not_active IP Right Cessation
- 2012-09-27 CA CA2848518A patent/CA2848518C/en not_active Expired - Fee Related
- 2012-09-27 EA EA201400392A patent/EA029834B1/ru not_active IP Right Cessation
- 2012-09-27 US US14/344,255 patent/US9586963B2/en active Active
-
2014
- 2014-03-13 IL IL231501A patent/IL231501B/en active IP Right Grant
- 2014-04-24 ZA ZA2014/02975A patent/ZA201402975B/en unknown
-
2015
- 2015-01-23 HK HK15100804.9A patent/HK1200448A1/xx not_active IP Right Cessation
-
2017
- 2017-03-06 US US15/450,919 patent/US10799510B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX356683B (es) | 2018-06-08 |
HK1200448A1 (en) | 2015-08-07 |
EP2760866B1 (en) | 2017-12-13 |
ZA201402975B (en) | 2015-04-29 |
US20170296548A1 (en) | 2017-10-19 |
JP6042438B2 (ja) | 2016-12-14 |
MX2014003637A (es) | 2014-09-22 |
CA2848518A1 (en) | 2013-04-04 |
BR112014006924B1 (pt) | 2020-10-06 |
AU2012314501A1 (en) | 2014-05-15 |
US9586963B2 (en) | 2017-03-07 |
IL231501B (en) | 2018-05-31 |
JP2014527996A (ja) | 2014-10-23 |
US10799510B2 (en) | 2020-10-13 |
BR112014006924A2 (pt) | 2017-04-11 |
US20150038503A1 (en) | 2015-02-05 |
EP2760866A1 (en) | 2014-08-06 |
IL231501A0 (en) | 2014-05-28 |
CA2848518C (en) | 2019-06-18 |
AU2012314501B2 (en) | 2017-02-16 |
EA029834B1 (ru) | 2018-05-31 |
WO2013045519A1 (en) | 2013-04-04 |
CN104024259A (zh) | 2014-09-03 |
BR112014006924A8 (pt) | 2018-01-09 |
CN104024259B (zh) | 2017-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201400392A1 (ru) | ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb | |
CY1120429T1 (el) | Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων | |
EA201590930A1 (ru) | Лекарственные формы руксолитиниба с замедленным высвобождением | |
EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
MX2016003456A (es) | Compuestos aminopirimidina sustituidos y metodos de uso. | |
MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
CL2008003056A1 (es) | Compuestos derivados de 3-fenil-imidazo[1,2-a]piridinas; composicion farmaceutica; proceso para su preparacion, util como inhibidores de alk-5 o alk-4 en el tratamiento de enfermedades inflamatorias u obstructivas de las vias respiratorias, cancer, enfermedades musculares, trastornos esqueleticos | |
EA201500365A1 (ru) | Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака | |
BR112013032720A2 (pt) | "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados" | |
EA201391029A1 (ru) | Производные оксазина и их применение при лечении неврологических нарушений | |
EA201590663A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ | |
EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
UA111588C2 (uk) | Композиція інгібітора jak для місцевого застосування | |
EA201590343A1 (ru) | Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
MX2010007683A (es) | Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met. | |
EA201291098A1 (ru) | Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ | |
PE20121617A1 (es) | Derivados de oxazina como inhibidores de bace | |
EA200900178A1 (ru) | Конденсированные гетероциклические производные и их применение | |
MX349004B (es) | Nuevos compuestos. | |
EA201400161A1 (ru) | Замещенные гетероароматические пиразолсодержащие карбоксамидные и мочевинные производные в качестве лигандов ваниллоидных рецепторов | |
EA201290878A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ, ПСИХИАТРИЧЕСКИХ И МЕТАБОЛИЧЕСКИХ РАССТРОЙСТВ И ЗАБОЛЕВАНИЙ | |
ECSP10010226A (es) | Compuestos derivados de amina para tratar enfermedades y trastornos oftálmicos | |
EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |